成人免费xx,国产又黄又湿又刺激不卡网站,成人性视频app菠萝网站,色天天天天

Home Cart 0 Sign in  

[ CAS No. 1744-22-5 ] {[proInfo.proName]}

,{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]}
HazMat Fee +

There will be a HazMat fee per item when shipping a dangerous goods. The HazMat fee will be charged to your UPS/DHL/FedEx collect account or added to the invoice unless the package is shipped via Ground service. Ship by air in Excepted Quantity (each bottle), which is up to 1g/1mL for class 6.1 packing group I or II, and up to 25g/25ml for all other HazMat items.

Type HazMat fee for 500 gram (Estimated)
Excepted Quantity USD 0.00
Limited Quantity USD 15-60
Inaccessible (Haz class 6.1), Domestic USD 80+
Inaccessible (Haz class 6.1), International USD 150+
Accessible (Haz class 3, 4, 5 or 8), Domestic USD 100+
Accessible (Haz class 3, 4, 5 or 8), International USD 200+
Chemical Structure| 1744-22-5
Chemical Structure| 1744-22-5
Structure of 1744-22-5 * Storage: {[proInfo.prStorage]}

Please Login or Create an Account to: See VIP prices and availability

Cart0 Add to My Favorites Add to My Favorites Bulk Inquiry Inquiry Add To Cart

Search after Editing

* Storage: {[proInfo.prStorage]}

* Shipping: {[proInfo.prShipping]}

Quality Control of [ 1744-22-5 ]

Related Doc. of [ 1744-22-5 ]

Alternatived Products of [ 1744-22-5 ]
Product Citations

Product Citations      Expand+

Kim, Jaejeong ; Kang, Changyu ; Jung, Yunjin DOI:

Abstract: Purpose: In our previous study, (RLZ) azo-linked to (RAS) was prepared as a colon-targeted RLZ prodrug against rat colitis. However, was not a satisfactory colon-targeted prodrug because of its non-negligible systemic absorption, leading to low colonic delivery efficiency and the ability to limit the systemic absorption of RLZ. This study aimed to improve the colon specificity and anticolitic activity of . Methods: (SA) was conjugated with the acidic amino acids (Asp) and (Glu) and subsequently azo-coupled with to yield Asp-conjugated (RAS-Asp) and Glu-conjugated (RAS-Glu). Results: Amino acid-conjugated lowered the distribution coefficient and cell permeability of while exhibiting a release profile of RLZ similar to that of in the cecal contents. Upon oral gavage, amino acid-conjugated delivered a larger amount of RLZ to the cecum than . The ability of amino acid-conjugated to limit the systemic absorption of RLZ was greater than that of . No significant differences were observed in the colon-specific performance between RAS-Asp and RAS-Glu. In a DNBS-induced rat colitis model, amino acid-conjugated was more effective than in ameliorating colonic damage and inflammation and modulating the anti-inflammatory GSK3β-IL-10 pathway in the inflamed colon, without a significant difference between RAS-Asp and RAS-Glu. Conclusion: Conjugation of acidic amino acids with improved the colon specificity, anticolitic activity, and safety of . N-Salicyloyl acidic amino acids may act as high-performance colon-specific promiety for a candidate drug modifiable to a colon-targeted prodrug with an azo bond as a colon-specific link.

Keywords: ; Colon-targeted prodrug ; Colitis ; Acidic amino acids ; High performance colon-specific promoiety

Purchased from AmBeed: ; ; ;

Kim, Jaejeong ; Kang, Changyu ; Yoo, Jin-Wook , et al. DOI: PubMed ID:

Abstract: In our previous study, riluzole azo-linked to salicylic acid (RAS) was prepared as a colon-targeted prodrug of riluzole (RLZ) to facilitate the repositioning of RLZ as an anticolitic drug. RAS is more effective against rat colitis than RLZ and sulfasalazine, currently used as an anti-inflammatory bowel disease drug. The aim of this study is to further improve colon specificity, anticolitic potency, and safety of RAS. N-succinylaspart-1-ylRLZ (SAR) and N-succinylglutam-1-ylRLZ (SGR) were synthesized and evaluated as a ""me-better"" colon-targeted prodrug of RLZ against rat colitis. SAR but not SGR was converted to RLZ in the cecal contents, whereas both conjugates remained intact in the small intestine. When comparing the colon specificity of SAR with that of RAS, the distribution coefficient and cell permeability of SAR were lower than those of RAS. In parallel, oral SAR delivered a greater amount of RLZ to the cecum of rats than oral RAS. In a DNBS-induced rat model of colitis, oral SAR mitigated colonic damage and inflammation and was more potent than oral RAS. Moreover, upon oral administration, SAR had a greater ability to limit the systemic absorption of RLZ than RAS, indicating a reduced risk of systemic side effects of SAR. Taken together, SAR may be a "me-better" colon-targeted prodrug of RLZ to improve the safety and anticolitic potency of RAS, an azo-type colon-targeted prodrug of RLZ.

Keywords: riluzole ; colon-targeted drug delivery ; colitis ; prodrug ; N-succinylated acidic amino acids

Purchased from AmBeed: ; ; ;

Product Details of [ 1744-22-5 ]

CAS No. :1744-22-5 MDL No. :MFCD00210213
Formula : C8H5F3N2OS Boiling Point : -
Linear Structure Formula :- InChI Key :FTALBRSUTCGOEG-UHFFFAOYSA-N
M.W : 234.20 Pubchem ID :5070
Synonyms :
PK 26124;RP-54274;Riluzole, Rilutek, PK 26124, PK26124, PK-26124, RP 54274, RP54274
Chemical Name :6-(Trifluoromethoxy)benzo[d]thiazol-2-amine

Calculated chemistry of [ 1744-22-5 ]      Expand+

Physicochemical Properties

Num. heavy atoms : 15
Num. arom. heavy atoms : 9
Fraction Csp3 : 0.12
Num. rotatable bonds : 2
Num. H-bond acceptors : 5.0
Num. H-bond donors : 1.0
Molar Refractivity : 50.71
TPSA : 76.38 ?2

Pharmacokinetics

GI absorption : High
BBB permeant : Yes
P-gp substrate : No
CYP1A2 inhibitor : Yes
CYP2C19 inhibitor : Yes
CYP2C9 inhibitor : No
CYP2D6 inhibitor : No
CYP3A4 inhibitor : No
Log Kp (skin permeation) : -5.17 cm/s

Lipophilicity

Log Po/w (iLOGP) : 2.04
Log Po/w (XLOGP3) : 3.61
Log Po/w (WLOGP) : 4.05
Log Po/w (MLOGP) : 1.44
Log Po/w (SILICOS-IT) : 2.93
Consensus Log Po/w : 2.81

Druglikeness

Lipinski : 0.0
Ghose : None
Veber : 0.0
Egan : 0.0
Muegge : 0.0
Bioavailability Score : 0.55

Water Solubility

Log S (ESOL) : -3.88
Solubility : 0.031 mg/ml ; 0.000132 mol/l
Class : Soluble
Log S (Ali) : -4.9
Solubility : 0.00294 mg/ml ; 0.0000126 mol/l
Class : Moderately soluble
Log S (SILICOS-IT) : -3.25
Solubility : 0.133 mg/ml ; 0.000569 mol/l
Class : Soluble

Medicinal Chemistry

PAINS : 0.0 alert
Brenk : 0.0 alert
Leadlikeness : 2.0
Synthetic accessibility : 2.24

Safety of [ 1744-22-5 ]

Signal Word:Danger Class:6.1
Precautionary Statements:P264-P270-P301+P310+P330-P405-P501 UN#:2811
Hazard Statements:H300 Packing Group:Ⅱ
GHS Pictogram:

Application In Synthesis of [ 1744-22-5 ]

* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.

  • Downstream synthetic route of [ 1744-22-5 ]

[ 1744-22-5 ] Synthesis Path-Downstream   1~3

  • 1
  • [ 116668-47-4 ]
  • [ 530-62-1 ]
  • [ 1744-22-5 ]
  • 6-[3-(6-trifluoromethoxy-benzothiazol-2-yl)-ureido]-naphthalene-2-carboxylic acid [ No CAS ]
  • 2
  • [ 6557-86-4 ]
  • [ 1744-22-5 ]
  • N-[6-(trifluoromethoxy)benzothiazol-2-yl]cycloheptanecarboxamide [ No CAS ]
  • 3
  • [ 41360-32-1 ]
  • [ 1744-22-5 ]
  • C16H11F3N2O5S2 [ No CAS ]
Recommend Products
Same Skeleton Products

Technical Information

Historical Records

Similar Product of
[ 1744-22-5 ]

Chemical Structure| 1215552-03-6

A1230135[ 1215552-03-6 ]

Riluzole-13C,15N2

Reason: Stable Isotope

; ;